Literature DB >> 22284640

Dosimetric research on intensity-modulated arc radiotherapy planning for left breast cancer after breast-preservation surgery.

Yong Yin1, Jinhu Chen, Tao Sun, Changsheng Ma, Jie Lu, Tonghai Liu, Ruozheng Wang.   

Abstract

Intensity-modulated radiotherapy (IMRT) has played an important role in breast cancer radiotherapy after breast-preservation surgery. Our aim was to study the dosimetric and implementation features/feasibility between IMRT and intensity-modulated arc radiotherapy (Varian RapidArc, Varian, Palo Alto, CA). The forward IMRT plan (f-IMRT), the inverse IMRT, and the RapidArc plan (RA) were generated for 10 patients. Afterward, we compared the target dose distribution of the 3 plans, radiation dose on organs at risk, monitor units, and treatment time. All 3 plans met clinical requirements, with RA performing best in target conformity. In target homogeneity, there was no statistical significance between RA and IMRT, but both of homogeneity were less than f-IMRT's. With regard to the V(5) and V(10) of the left lung, those in RA were higher than in f-IMRT but were lower than in IMRT; for V(20) and V(30), the lowest was observed in RA; and in the V(5) and V(10) of the right lung, as well as the mean dose in normal-side breast and right lung, there was no statistically significance difference between RA and IMRT, and the lowest value was observed in f-IMRT. As for the maximum dose in the normal-side breast, the lowest value was observed in RA. Regarding monitor units (MUs), those in RA were higher than in f-IMRT but were lower than in IMRT. Treatment time of RA was 84.6% and 88.23% shorter than f-IMRT and IMRT, respectively, on average. Compared with f-IMRT and IMRT, RA performed better in target conformity and can reduce high-dose volume in the heart and left lung-which are related to complications-significantly shortening treatment time as well. Compared with IMRT, RA can also significantly reduce low-dose volume and MUs of the afflicted lung.
Copyright © 2012 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22284640     DOI: 10.1016/j.meddos.2011.11.001

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  12 in total

1.  Helical tomotherapy and volumetric modulated arc therapy: New therapeutic arms in the breast cancer radiotherapy.

Authors:  Olivier Lauche; Youlia M Kirova; Pascal Fenoglietto; Emilie Costa; Claire Lemanski; Celine Bourgier; Olivier Riou; David Tiberi; Francois Campana; Alain Fourquet; David Azria
Journal:  World J Radiol       Date:  2016-08-28

2.  Performance of a Knowledge-Based Model for Optimization of Volumetric Modulated Arc Therapy Plans for Single and Bilateral Breast Irradiation.

Authors:  Antonella Fogliata; Giorgia Nicolini; Celine Bourgier; Alessandro Clivio; Fiorenza De Rose; Pascal Fenoglietto; Francesca Lobefalo; Pietro Mancosu; Stefano Tomatis; Eugenio Vanetti; Marta Scorsetti; Luca Cozzi
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

Review 3.  Treatment techniques to reduce cardiac irradiation for breast cancer patients treated with breast-conserving surgery and radiation therapy: a review.

Authors:  Robert E Beck; Leonard Kim; Ning J Yue; Bruce G Haffty; Atif J Khan; Sharad Goyal
Journal:  Front Oncol       Date:  2014-11-14       Impact factor: 6.244

4.  Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results.

Authors:  Fiorenza De Rose; Antonella Fogliata; Davide Franceschini; Piera Navarria; Elisa Villa; Cristina Iftode; Giuseppe D'Agostino; Luca Cozzi; Francesca Lobefalo; Pietro Mancosu; Stefano Tomatis; Marta Scorsetti
Journal:  Radiat Oncol       Date:  2016-09-17       Impact factor: 3.481

Review 5.  Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer.

Authors:  Luca Cozzi; Frank Lohr; Antonella Fogliata; Davide Franceschini; Fiorenza De Rose; A R Filippi; Gabriele Guidi; Valentina Vanoni; Marta Scorsetti
Journal:  Radiat Oncol       Date:  2017-12-19       Impact factor: 3.481

Review 6.  Dosimetric evaluation and systematic review of radiation therapy techniques for early stage node-negative breast cancer treatment.

Authors:  Tabitha Y Chan; Johann I Tang; Poh Wee Tan; Neill Roberts
Journal:  Cancer Manag Res       Date:  2018-10-23       Impact factor: 3.989

7.  Evaluation of sparing organs at risk (OARs) in left-breast irradiation in the supine and prone positions and with deep inspiration breath-hold.

Authors:  Amitpal Singh Saini; Catherine S Hwang; Matthew C Biagioli; Indra J Das
Journal:  J Appl Clin Med Phys       Date:  2018-06-21       Impact factor: 2.102

8.  Evaluation of a generalized knowledge-based planning performance for VMAT irradiation of breast and locoregional lymph nodes-Internal mammary and/or supraclavicular regions.

Authors:  Maria Rago; Lorenzo Placidi; Mattia Polsoni; Giulia Rambaldi; Davide Cusumano; Francesca Greco; Luca Indovina; Sebastiano Menna; Elisa Placidi; Gerardina Stimato; Stefania Teodoli; Gian Carlo Mattiucci; Silvia Chiesa; Fabio Marazzi; Valeria Masiello; Vincenzo Valentini; Marco De Spirito; Luigi Azario
Journal:  PLoS One       Date:  2021-01-15       Impact factor: 3.240

9.  Volumetric-modulated arc therapy for left-sided breast cancer and all regional nodes improves target volumes coverage and reduces treatment time and doses to the heart and left coronary artery, compared with a field-in-field technique.

Authors:  Marguerite Tyran; Hugues Mailleux; Agnes Tallet; Pierre Fau; Laurence Gonzague; Mathieu Minsat; Laurence Moureau-Zabotto; Michel Resbeut
Journal:  J Radiat Res       Date:  2015-09-19       Impact factor: 2.724

10.  Estimation of the risk of secondary malignancy arising from whole-breast irradiation: comparison of five radiotherapy modalities, including TomoHDA.

Authors:  Eun Young Han; Nava Paudel; Jiwon Sung; Myonggeun Yoon; Weon Kuu Chung; Dong Wook Kim
Journal:  Oncotarget       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.